Pfizer closed 2025 with $62.6 billion in revenue, ending the year as the world’s largest pharmaceutical company by sales despite a 2% decline. The company’s non-COVID portfolio grew 6% operationally, led by Eliquis, the Vyndaqel family, and Prevnar. This post breaks down the latest Pfizer Statistics 2026 covering revenue, top products, R&D spending, employees, and geographic mix.
Key Pfizer Statistics 2026
- Pfizer reported full-year 2025 revenue of $62.6 billion, a 2% decline from 2024.
- The non-COVID portfolio grew 6% operationally in 2025.
- R&D spending hit $10.4 billion in 2025, plus $8.8 billion in business development deals.
- Pfizer ended 2025 with about 75,000 employees, down 7.4% year-over-year.
- U.S. revenue accounted for $37.1 billion in 2025, or 59% of the global total.
Pfizer Revenue 2025: Annual Performance
Pfizer recorded full-year 2025 revenue of $62.6 billion, down from $63.6 billion in 2024. The decline came mostly from lower COVID-19 product sales, while the rest of the portfolio kept growing. Foreign exchange added a $247 million boost.
The company guided 2026 revenue between $59.5 billion and $62.5 billion, with COVID-19 products expected to contribute roughly $5 billion against $6.5 billion in 2025.
| Year | Revenue (USD) | Year-over-Year Change |
|---|---|---|
| 2021 | $81.3 billion | +92% |
| 2022 | $100.3 billion | +23% |
| 2023 | $58.5 billion | -42% |
| 2024 | $63.6 billion | +7% |
| 2025 | $62.6 billion | -2% |
| 2026 (guidance) | $59.5–$62.5 billion | -1% to -5% |
Source: Pfizer Q4 2025 Earnings Release
Pfizer Top-Selling Products 2025
Eliquis kept its spot as Pfizer’s top revenue driver in cardiovascular care, while the Vyndaqel family posted the strongest growth in the portfolio. Prevnar held steady, and Comirnaty bounced back in 2025 after softer prior quarters.
| Product | Category | 2025 Revenue (Approx.) |
|---|---|---|
| Eliquis | Anticoagulant | $8.0 billion |
| Vyndaqel family | Cardiovascular (ATTR-CM) | $6.7 billion |
| Prevnar family | Vaccine | $6.5 billion |
| Comirnaty | COVID-19 vaccine | $5.4 billion |
| Paxlovid | COVID-19 antiviral | $2.0 billion |
| Ibrance | Oncology | $4.4 billion |
| Padcev | Oncology | $1.9 billion |
Source: Pfizer Q4 2025 Earnings Release, SEC filings
Pfizer R&D Spending and Pipeline Investment
R&D spending reached $10.4 billion in 2025, slightly below the $10.8 billion spent in 2024. The reduction came from pipeline focus and lower compensation costs. Pfizer guided 2026 R&D spending between $10.5 billion and $11.5 billion as it picks up investment in PD-1 x VEGF bispecific work and Metsera obesity programs.
On top of internal R&D, Pfizer spent about $8.8 billion on business development in 2025, including the Metsera acquisition and a 3SBio in-licensing deal.
| Year | R&D Spending | % of Revenue |
|---|---|---|
| 2021 | $13.8 billion | 17.0% |
| 2022 | $11.4 billion | 11.4% |
| 2023 | $10.7 billion | 18.3% |
| 2024 | $10.8 billion | 17.0% |
| 2025 | $10.4 billion | 16.7% |
Source: Pfizer 10-K Filings, Macrotrends
Pfizer Employees: Workforce Statistics 2026
Pfizer ended 2025 with about 75,000 employees, down from 81,000 a year earlier. That’s a 7.4% drop and the lowest headcount since 2017. The decline reflects the cost realignment program targeting roughly $4.5 billion in savings by year-end 2025, plus an additional $500 million in 2025.
The company runs 37 manufacturing sites worldwide as of 2025.
| Year | Employees | Year-over-Year Change |
|---|---|---|
| 2020 | 88,300 | -4.4% |
| 2021 | 78,500 | -11.1% |
| 2022 | 79,000 | +0.6% |
| 2023 | 83,000 | +5.1% |
| 2024 | 81,000 | -2.4% |
| 2025 | 75,000 | -7.4% |
Source: Pfizer Annual 10-K Filings, StockAnalysis.com
Pfizer Revenue By Region 2025
The U.S. brought in $37.1 billion in 2025, or 59% of total revenue. International revenue from operations outside the U.S. came to $25.5 billion, with China and Japan called out as key markets in the company’s 10-K. Pfizer Statistics 2026 show emerging markets remain the smallest geographic segment.
| Region | 2025 Revenue | Share of Total |
|---|---|---|
| United States | $37.1 billion | 59.3% |
| Developed Rest of World | $16.2 billion | 25.9% |
| Emerging Markets | $9.3 billion | 14.9% |
Source: Pfizer 2025 Annual Report (Form 10-K)
Pfizer Market Cap and Stock Performance
Pfizer’s market cap stood at roughly $153 billion as of late April 2026, with the stock trading near $26.50. The market cap rose 9.3% over the prior 12 months. Pfizer paid a forward dividend yielding about 6.5%, one of the highest in big pharma.
The company’s adjusted diluted EPS for 2025 came in at $3.21, beating its earlier guidance range of $2.80–$3.00. For 2026, Pfizer reaffirmed adjusted EPS guidance of $2.80 to $3.00.
Pfizer Business Segments 2025
Pfizer reorganized into three segments in 2025: Biopharma (the main commercial business), PC1 (a separate biopharma unit), and Pfizer Ignite (services for biotech partners). Within Biopharma, Specialty Care grew 6% operationally in Q1 2025 while Primary Care fell 20% on Paxlovid declines.
| Segment | Q1 2025 Revenue | Operational Change |
|---|---|---|
| Primary Care | $5.7 billion | -20% |
| Specialty Care | $4.0 billion | +6% |
| Oncology | $3.7 billion | +7% |
Source: Pfizer Q1 2025 Earnings Release
FAQs
What was Pfizer’s revenue in 2025?
Pfizer reported full-year 2025 revenue of $62.6 billion, down 2% from $63.6 billion in 2024. The decline came mainly from lower COVID-19 product sales, while non-COVID products grew 6% operationally.
What is Pfizer’s top-selling drug in 2025?
Eliquis was Pfizer’s top-selling drug in 2025, generating about $8 billion in revenue. The cardiovascular anticoagulant is co-marketed with Bristol-Myers Squibb and treats atrial fibrillation and blood clots.
How much does Pfizer spend on R&D?
Pfizer spent $10.4 billion on internal R&D in 2025, plus another $8.8 billion on business development deals including the Metsera acquisition. R&D spending equals roughly 17% of total revenue.
How many employees does Pfizer have in 2026?
Pfizer had approximately 75,000 employees at the end of 2025, down from 81,000 a year earlier. The 7.4% decline reflects the company’s cost realignment program targeting $4.5 billion in savings.
What is Pfizer’s market cap in 2026?
Pfizer’s market cap was roughly $153 billion as of late April 2026, with the stock trading near $26.50. The company ranks among the world’s 110 most valuable public companies.
